Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: Voxel-based-morphometry (VBM) study

References

• Berati-Giani D, Ricciardi-Castagnoli P, Kohler C, Cesura AM. 1996. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem 66:996–1004.
   PubMedGoogle Scholar
• Bertoli F, Espino M, Arosemena JR, Fishback JL, Frenkel JK. 1995. A spectrum in the pathology of toxoplasmosis in patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med 119:214–224.
   PubMed Web of Science ®Google Scholar
• Brown AS, Schaefer CA, Quesenberry CP Jr, Liu L, Babulas VP, Susser ES. 2005. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry 162:767–773.
   PubMed Web of Science ®Google Scholar
• Bubenikova-Valesova V, Horacek J, Vrajova M, Hoschl C. 2008. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 32:1014–1023.
   PubMed Web of Science ®Google Scholar
• Carruthers VB, Suzuki Y. 2007. Effects of Toxoplasma gondii infection on the brain. Schizophr Bull 33:745–751.
   PubMed Web of Science ®Google Scholar
• Ceravolo IP, Chaves AC, Bonjardim CA, Sibley D, Romanha AJ, Gazzinelli RT. 1999. Replication of Toxoplasma gondii, but not Trypanosoma cruzi, is regulated in human fibroblasts activated with gamma interferon: requirement of a functional JAK/STAT pathway. Infect Immun 67:2233–2240.
   PubMed Web of Science ®Google Scholar
• Chan RC, Di X, McAlonan GM, Gong QY. 2011. Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophr Bull 37:177 188.
   Google Scholar
• Dubey JP. 1998. Advances in the life cycle of Toxoplasma gondii. Int J Parasitol 28:1019–1024.
   PubMed Web of Science ®Google Scholar
• el-Defrawy SR, Boegman RJ, Jhamandas K, Beninger RJ. 1986. The neurotoxic actions of quinolinic acid in the central nervous system. Can J Physiol Pharmacol 64:369–375.
   PubMedGoogle Scholar
• Ferguson DJ, Hutchison WM. 1987. The host-parasite relationship of Toxoplasma gondii in the brains of chronically infected mice. Virchows Arch A Pathol Anat Histopathol 411:39–43.
   PubMedGoogle Scholar
• Fernandes JF, Taketomi EA, Mineo JR, Miranda DO, Alves R, Resende RO, . 2010. Antibody and cytokine responses to house dust mite allergens and Toxoplasma gondii antigens in atopic and non-atopic Brazilian subjects. Clin Immunol 136:148–156.
   PubMedGoogle Scholar
• Flegr J, Preiss M, Klose J, Havlicek J, Vitakova M, Kodym P. 2003. Decreased level of psychobiological factor novelty seeking and lower intelligence in men latently infected with the protozoan parasite Toxoplasma gondii dopamine, a missing link between schizophrenia and toxoplasmosis? Biol Psychol 63:253–268.
   PubMed Web of Science ®Google Scholar
• Fornito A, Yucel M, Patti J, Wood SJ, Pantelis C. 2009. Mapping grey matter reductions in schizophrenia: an anatomical likelihood estimation analysis of voxel-based morphometry studies. Schizophr Res 108:104–113.
   PubMed Web of Science ®Google Scholar
• Gaskell EA, Smith JE, Pinney JW, Westhead DR, McConkey GA. 2009. A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PLoS One 4:e4801.
   PubMed Web of Science ®Google Scholar
• Glahn DC, Laird AR, Ellison-Wright I, Thelen SM, Robinson JL, Lancaster JL, . 2008. Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol Psychiatry 64:774–781.
   PubMed Web of Science ®Google Scholar
• Halonen SK, Lyman WD, Chiu FC. 1996. Growth and development of Toxoplasma gondii in human neurons and astrocytes. J Neuropathol Exp Neurol 55:1150–1156.
   PubMedGoogle Scholar
• Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. 2001. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol 154: 357–365.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276.
   PubMed Web of Science ®Google Scholar
• Kessler M, Terramani T, Lynch G, Baudry M. 1989. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319–1328.
   PubMed Web of Science ®Google Scholar
• Kodym P, Machala L, Rohacova H, Sirocka B, Maly M. 2007. Evaluation of a commercial IgE ELISA in comparison with IgA and IgM ELISAs, IgG avidity assay and complement fixation for the diagnosis of acute toxoplasmosis. Clin Microbiol Infect 13:40–47.
   PubMedGoogle Scholar
• Lancaster JL, Tordesillas-Gutierrez D, Martinez M, Salinas F, Evans A, Zilles K, . 2007. Bias between MNI and Talairach coordinates analyzed using the ICBM-152 brain template. Hum Brain Mapp 28:1194–1205.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, . 2004. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 161(2 Suppl):1–56.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, . 2004. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:4–8.
   PubMed Web of Science ®Google Scholar
• Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. 2004. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 15:618–629.
   PubMed Web of Science ®Google Scholar
• Miller CL, Llenos IC, Dulay JR, Weis S. 2006. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073– 1074:25–37.
   Google Scholar
• Mortensen PB, Norgaard-Pedersen B, Waltoft BL, Sorensen TL, Hougaard D, Yolken RH. 2007. Early infections of Toxoplasma gondii and the later development of schizophrenia. Schizophr Bull 33:741–744.
   PubMed Web of Science ®Google Scholar
• Nagineni CN, Pardhasaradhi K, Martins MC, Detrick B, Hooks JJ. 1996. Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect Immun 64:4188–4196.
   PubMed Web of Science ®Google Scholar
• Oldfield RC. 1971. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9:97–113.
   PubMed Web of Science ®Google Scholar
• Pell GS, Briellmann RS, Chan CH, Pardoe H, Abbott DF, Jackson GD. 2008. Selection of the control group for VBM analysis: influence of covariates, matching and sample size. Neuroimage 41:1324–1335.
   PubMed Web of Science ®Google Scholar
• Schwarcz R, Hunter CA. 2007. Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid? Schizophr Bull 33:652–653.
   PubMedGoogle Scholar
• Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. 2001. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521–530.
   PubMed Web of Science ®Google Scholar
• Silva NM, Rodrigues CV, Santoro MM, Reis LF, Varez-Leite JI, Gazzinelli RT. 2002. Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1. Infect Immun 70:859–868.
   PubMed Web of Science ®Google Scholar
• Smythies J. 1999. The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion. Neurotox Res 1: 27–39.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Claflin J, Wang X, Lengi A, Kikuchi T. 2005. Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplasma gondii. Int J Parasitol 35:83–90.
   PubMedGoogle Scholar
• Tiwari AK, Zai CC, Muller DJ, Kennedy JL. 2010. Genetics in schizophrenia: where are we and what next? Dialogues Clin Neurosci 12:289–303.
   PubMedGoogle Scholar
• Torrey EF, Bartko JJ, Lun ZR, Yolken RH. 2007. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull 33:729–736.
   PubMed Web of Science ®Google Scholar
• Wang HL, Wang GH, Li QY, Shu C, Jiang MS, Guo Y. 2006. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand 114: 40–48.
   PubMed Web of Science ®Google Scholar
• Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H. 1996. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246: 279–284.
   PubMed Web of Science ®Google Scholar
• Woods SW. 2003. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663–667.
   PubMed Web of Science ®Google Scholar